Evaluation of risk factors for cytomegalovirus DNAemia after end of regular prophylaxis after heart transplantation.

Moritz Benjamin ImmohrDaniel OehlerFreya Sophie JenkinsNikolas KalampokasVincent Hendrik HettlichDennis SigettiFabian VoßHannan DalyanogluHug AubinPayam AkhyariArtur LichtenbergUdo Boeken

Published in: Immunity, inflammation and disease (2023)

Our data should raise awareness of CMV-DNAemia after the termination of regular prophylaxis, as this affects one in five HTx patients. Especially old recipients as well as D+/R- and D-/R+ serology share an elevated risk of late CMV-DNAemia. For these patients, prolongation, or repetition of CMV prophylaxis, including antiviral drugs and CMV immunoglobulins, may be considered.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
machine learning
patient reported outcomes
diffuse large b cell lymphoma